CR6086   Click here for help

GtoPdb Ligand ID: 9845

Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: CR6086 is a potent and selective prostaglandin E2 receptor 4 (EP4) antagonist that that is being investigated for immunomodulatory potential, that may be suitable for the treatment of rheumatoid arthritis [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 2
Rotatable bonds 8
Topological polar surface area 69.64
Molecular weight 472.2
XLogP 5.23
No. Lipinski's rules broken 1
Click here for help
Canonical SMILES O=C(C1CC2(CCN1Cc1ccc(cc1)C(F)(F)F)CC2)NC1(CC1)c1ccc(cc1)C(=O)O
Isomeric SMILES O=C([C@H]1CC2(CCN1Cc1ccc(cc1)C(F)(F)F)CC2)NC1(CC1)c1ccc(cc1)C(=O)O
InChI InChI=1S/C26H27F3N2O3/c27-26(28,29)20-5-1-17(2-6-20)16-31-14-13-24(9-10-24)15-21(31)22(32)30-25(11-12-25)19-7-3-18(4-8-19)23(33)34/h1-8,21H,9-16H2,(H,30,32)(H,33,34)/t21-/m1/s1
No information available.
Summary of Clinical Use Click here for help
A proof-of-concept clinical trial evaluating CR6086 plus methotrexate in RA patients with early stage disease and who are DMARD-naive is underway- see NCT03163966.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03163966 A Study of the EP4 Antagonist CR6086 in Combination With Methotrexate, in DMARD-naïve Patients With Early Rheumatoid Arthritis Phase 2 Interventional Rottapharm Biotech